Companies
Broad Institute
Genetic Perturbation Platform (GPP) — reference genome-wide libraries.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ |
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdanmpaema
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | Broad Institute of MIT and Harvard | broadinstitute.org |
| Research focus | Development and application of functional genomic tools, including CRISPR technologies for large-scale genetic screens, gene expression, and RNA interference. | portals.broadinstitute.org · broadinstitute.org |
| Principal staff | David Root (Senior Director), John Doench (Senior Director R&D) | broadinstitute.org |
| Publications | Over 9,716 total publications to date (for the Broad Institute as a whole) | broadinstitute.org |
| Partnership | Functional Genomics Consortium (including AbbVie, Bristol Myers Squibb, Janssen, Merck, and Vir Biotechnology) medium confidence | nature.com |
| Partnership | Center for Basic Metabolic Research (CBMR) at the University of Copenhagen medium confidence | cbmr.ku.dk |
Independent sources: cbmr.ku.dk · nature.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Base editing | genome-engineering | Medium | → |
| CRISPR screening as a service | genome-engineering | Low | → |
| Long-read sequencing services | bioinformatics-omics | Medium | → |
| Prime editing | genome-engineering | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.